<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422435</url>
  </required_header>
  <id_info>
    <org_study_id>The PreCiSE Trial: CP-03</org_study_id>
    <nct_id>NCT00422435</nct_id>
  </id_info>
  <brief_title>CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation</brief_title>
  <official_title>The PreCiSE Trial: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conor Medsystems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the performance and safety of a new catheter system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate acute Device Success, defined as attainment of &lt;50%&#xD;
      residual stenosis of the target lesion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Success</measure>
    <time_frame>At procedure or hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>30 days, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>30 days, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device Performance</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital, 30-day, 6-month, 12-month MACE</measure>
    <time_frame>30-day, 6-month, 12-month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter</intervention_name>
    <description>Paclitaxel-Eluting Coronary Stent</description>
    <arm_group_label>Drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥18 years of age&#xD;
&#xD;
          -  Eligible for percutaneous coronary intervention&#xD;
&#xD;
          -  Documented stable or unstable angina pectoris (Canadian Cardiovascular Society&#xD;
             Classification 1, 2, 3, or 4), documented ischemia, or documented silent ischemia&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥25% documented within the last 6 wks&#xD;
&#xD;
          -  Acceptable candidate for coronary artery bypass graft surgery&#xD;
&#xD;
          -  A single de novo lesion per study subject may be treated with the study device&#xD;
&#xD;
          -  Each target lesion may be composed of multiple lesions but must be completely&#xD;
             coverable by 1 study stent&#xD;
&#xD;
          -  Cumulative target lesion length per vessel ≤30 mm based on a visual estimate&#xD;
&#xD;
          -  RVD ≥2.5 mm to ≤3.0 mm based on a visual estimate&#xD;
&#xD;
          -  Target lesion diameter stenosis ≥50% and &lt;100% based on a visual estimate&#xD;
&#xD;
          -  Target vessel has not undergone prior revascularization within the preceding 6 months&#xD;
&#xD;
          -  Target lesion must be a minimum 10 mm distance from any previously treated segment of&#xD;
             the target vessel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: Translute or&#xD;
             PLGA&#xD;
&#xD;
          -  Planned treatment with any other PCI device in the target vessel(s)&#xD;
&#xD;
          -  MI within 72 hours prior to the index procedure&#xD;
&#xD;
          -  Patient is in cardiogenic shock&#xD;
&#xD;
          -  Cerebrovascular Accident within the past 6 months&#xD;
&#xD;
          -  Acute or chronic renal dysfunction (creatinine &gt;2.0 mg/dl or &gt;150 µmol/L)&#xD;
&#xD;
          -  Contraindication to ASA or to clopidogrel&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt;100, 000/mm3)&#xD;
&#xD;
          -  Active gastrointestinal bleeding within the past three months&#xD;
&#xD;
          -  Any prior true anaphylactic reaction to contrast agents&#xD;
&#xD;
          -  Patient is currently, or has been treated with paclitaxel (systemic) within 12 months&#xD;
             of the index procedure&#xD;
&#xD;
          -  Female of childbearing potential with a positive pregnancy test within 7 days before&#xD;
             the index procedure, or lactating, or intends to become pregnant during the study&#xD;
&#xD;
          -  Life expectancy of less than 24 months due to other medical conditions&#xD;
&#xD;
          -  Co-morbid condition(s) that could limit the patient's ability to participate in the&#xD;
             study, compliance with follow-up requirements or impact the scientific integrity of&#xD;
             the study&#xD;
&#xD;
          -  Currently participating in another investigational drug or device study that has not&#xD;
             completed the primary endpoint or that clinically interferes with the endpoints of&#xD;
             this study&#xD;
&#xD;
          -  Left main coronary artery disease (stenosis &gt;50%), whether protected or unprotected&#xD;
&#xD;
          -  Target lesion is ostial in location (within 3.0 mm of vessel origin)&#xD;
&#xD;
          -  Target lesion and/or target vessel proximal to the target lesion is severely calcified&#xD;
             by visual estimation&#xD;
&#xD;
          -  Target lesion involves a bifurcation with a diseased (&gt;50% stenotic) branch vessel&#xD;
             &gt;2.0 mm in diameter that requires intervention&#xD;
&#xD;
          -  Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1)&#xD;
&#xD;
          -  Angiographic presence of probable or definite thrombus&#xD;
&#xD;
          -  Target vessel will be pre-treated with an unapproved device, directional or rotational&#xD;
             coronary atherectomy, laser, cutting balloon or transluminal extraction catheter&#xD;
             immediately prior to stent placement&#xD;
&#xD;
          -  Prior coronary intervention using brachytherapy to any segment of the target vessel&#xD;
&#xD;
          -  The target vessel has had prior drug-eluting stent placement to vessel segment (or&#xD;
             branch) proximal to intended target lesion site&#xD;
&#xD;
          -  Angiographic restenosis of any segment of the target vessel that has undergone prior&#xD;
             percutaneous coronary intervention&#xD;
&#xD;
          -  Angiographic evidence of atherosclerotic disease with &gt; 50% diameter stenosis (by&#xD;
             visual estimate) proximal or distal to the target lesion (applies to the major&#xD;
             epicardial portion of the target vessel and contiguous vessel segment if the target&#xD;
             lesion is located in a branch vessel)&#xD;
&#xD;
          -  Prior surgical revascularization of the target vessel with patent graft (saphenous&#xD;
             vein graft or arterial conduit)&#xD;
&#xD;
          -  Target lesion lies within 10 mm of prior surgical anastomosis site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Dubois, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Christophe Dubois, M.D. Principal Investigator</name_title>
    <organization>UH Gasthuisberg</organization>
  </responsible_party>
  <keyword>Percutaneous coronary intervention (PCI)</keyword>
  <keyword>Drug eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

